| NCT ID | NCT05470920 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Epithelial Ovarian Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 350 participants |
| Start Date | 2022-10-14 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 350 participants in total. It began in 2022-10-14 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a randomized trial to evaluate the effectiveness of an electronic decision aid tool versus a traditional genetic counselor session for multi-gene panel testing for people with ovarian or pancreatic cancer
Eligibility Criteria
Inclusion Criteria: * 18 years or older * Being seen in clinic at Massachusetts General Hospital or Boston Medical Center * Diagnosed with malignant epithelial ovarian carcinoma or malignant pancreatic adenocarcinoma. Exclusion Criteria : * Unable or unwilling to provide informed consent, undergo randomization, or complete the surveys associated with the study * Previous germline genetic testing * History of hereditary pancreatitis * Members of the following vulnerable populations: adults unable to consent, individuals who are not yet adults
Contact & Investigator
Daniel C. Chung, MD
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT05470920 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Epithelial Ovarian Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05470920 currently recruiting?
Yes, NCT05470920 is actively recruiting participants. Contact the research team at Chung.daniel@mgh.harvard.edu for enrollment information.
Where is the NCT05470920 trial being conducted?
This trial is being conducted at Boston, United States, Danvers, United States.
Who is sponsoring the NCT05470920 clinical trial?
NCT05470920 is sponsored by Massachusetts General Hospital. The principal investigator is Daniel C. Chung, MD at Massachusetts General Hospital. The trial plans to enroll 350 participants.